UPDATE 1-Cumberland says FDA extends liver drug review date

* FDA extends review date by 3 months to December

* Co trying to get drug approved for liver failure

* Drug already approved to treat acetaminophen overdose

* Shares down 10 pct in after-hours trade

Aug 20 (BestGrowthStock) – Cumberland Pharmaceuticals Inc (CPIX.O: )
said the U.S. regulator extended the review date for the
company’s drug for acute liver failure by three months to
December, sending its shares down 10 percent after market.

The drug, Acetadote, is already approved to treat the
overdose of a widely used over-the-counter painkiller,
acetaminophen, which can lead to liver damage.
Cumberland is trying to get the drug, generically known as
acetylcysteine, approved for acute liver failure induced by
reasons other than acetaminophen overdose.

Shares of the Nashville, Tennessee-based company were down
10 percent to $5.40 in after-hours trade. The shares, which
have lost more than half of their value over the past six
months, closed at $6.02 Friday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Unnikrishnan

UPDATE 1-Cumberland says FDA extends liver drug review date